Drug Profile
Research programme: targeted MRI contrast agents - Guerbet/ImaRx Therapeutics
Alternative Names: Targeted MRI contrast agents research programme - Guerbet/ImaRx TherapeuticsLatest Information Update: 14 May 2007
Price :
$50
*
At a glance
- Originator Guerbet; ImaRx Therapeutics
- Class Contrast media
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Dec 2004 Preclinical trials in Cancer diagnosis in USA (Injection)